(46 days)
iBond Self Etch is used for bonding of direct light-cured composite restorations (including Polyglas and copomers), bonding of indirect restorations in combination with a light-curing luting cement; porcelain, Polyglas®, and composite restorations (inlays, onlays, veneers, crowns) and sealing hypersensitive areas of teeth.
iBond Self Etch(new formulation is an acetone/water-based formulation of light activated methylacrylate resins.
The provided text refers to a dental bonding agent, iBond Self Etch, and its new formulation. The "study" described is a declaration of substantial equivalence to a predicate device, focusing on material properties and biocompatibility rather than a clinical trial in the traditional sense of comparing AI performance to human performance. As such, many of the requested elements for AI/MRMC studies are not applicable.
Here's an analysis of the provided information:
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria (Predicate) | Reported Device Performance (New iBond Self Etch) |
|---|---|
| Shear Bond Strength: >15 MPa | Shear Bond Strength: ≥20 MPa |
| Storage condition: Refrigeration required | Storage condition: No refrigeration required |
| Handling: Shaking necessary | Handling: No shaking necessary |
2. Sample Size Used for the Test Set and Data Provenance
- The document describes a modification to an existing device (iBond Self Etch) and a comparison to its predicate (HK Bond K063062).
- The "test set" in this context refers to the samples of the new formulation used for laboratory testing of properties like shear bond strength.
- Sample Size: Not explicitly stated for each test, but it is implied that standard laboratory testing procedures were followed for material characterization.
- Data Provenance: The studies were conducted internally by Heraeus Kulzer, LLC. The document does not specify country of origin for the data (beyond the applicant being in the US) or if it's retrospective or prospective, but it implies prospective lab testing of the new formulation.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications
- Not applicable. This is not a study requiring human expert assessment for ground truth. The "ground truth" for material characteristics like shear bond strength is established by standardized laboratory testing protocols, not expert consensus.
4. Adjudication Method for the Test Set
- Not applicable for the reasons stated above.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance
- Not applicable. This is not an AI device, and therefore no MRMC study was conducted or is relevant.
6. If a Standalone (i.e., algorithm only without human-in-the loop performance) Was Done
- Not applicable. This is not an AI device.
7. The Type of Ground Truth Used (expert consensus, pathology, outcomes data, etc.)
- For the material properties (e.g., pH, refractive index, shear bond strength), the ground truth is established through objective, standardized laboratory measurements following established protocols relevant to dental materials.
- For biocompatibility, the ground truth is based on adherence to international standards (EN ISO 10993) and a toxicological assessment of leachable compounds.
8. The Sample Size for the Training Set
- Not applicable. This is not an AI device, so there is no "training set." The understanding of the device's formulation and properties comes from chemical development and iterative laboratory testing, not machine learning training.
9. How the Ground Truth for the Training Set Was Established
- Not applicable for the reasons stated above.
Summary of the "Study" (Rationale for Substantial Equivalence):
The submission argues for substantial equivalence by demonstrating that the new iBond Self Etch formulation is comparable to its predicate (HK Bond K063062) despite minor modifications (addition of a stabilizer, change in rheological additive). The key elements of the "study" are:
- Comparison of Technical Characteristics: A detailed table highlights that many parameters (content of BHT, indications for use, visual appearance, pH, refractive index, application, dwell time, curing time, compatibility) remain the same.
- Performance Testing: The crucial difference in shear bond strength was tested, and the new formulation exceeded the predicate's performance requirement (>15 MPa for predicate vs. ≥20 MPa for new formulation).
- Biocompatibility Evaluation: The biological compatibility was verified in accordance with EN ISO 10993. A toxicologist reviewed the leachable compounds, concluding that the safety is equivalent to the predicate. No in vivo toxicity studies were performed on the new formulation due to low exposure and animal welfare, relying on the previous testing of the predicate and the toxicological assessment of leachable compounds.
- Risk Analysis: A risk analysis according to ISO 14791 was conducted, concluding that the safety of the new formulation is substantially equivalent.
- Improved Usability: The new formulation offers improved convenience (no refrigeration required, no shaking necessary) while maintaining or improving performance.
In essence, the study is a series of laboratory tests and regulatory assessments to confirm that the minor formulation changes do not negatively impact the device's safety and effectiveness and, in some cases, improve its performance and user convenience.
{0}------------------------------------------------
K1232-78
Taeus
510(k) Summary according to 21 CFR 807.92(c)
510(k) summary of safety and effectiveness information for iBond Seff Etch (new formulation)
| Submitter Information: | |
|---|---|
| Name | Heraeus Kulzer, LLC |
| Address | 300 Heraeus WaySouth Bend, IN 46614 |
| Phone Number | (574) 299-5421 |
| Fax Number | (574) 291-0080 |
| Establishment Registration Number | 1925223 |
| Name of Contact Person | Jamie Mearna |
| Date Prepared | December 3, 2012 |
| Name of Device: | iBond Self Etch |
| Trade or Proprietary Name | iBond Self Etch |
| Common or Usual Name | Resin Tooth Bonding Agent |
| Classification Name | Dental KLE |
| Device Classification | Class II |
| Classification Panel: | 76 Dental |
| Regulation: | 21 CFR 872.3200 |
| Product code (s): | KLE |
| Legally marketed devices(s) to whichequivalence is claimed: | HK Bond K063062 |
| Reason for 510(k) Submission: | This submission reports a modification to HKBond K063062 regarding the addition of astabilizer, change in rheological additive andstorage requirements. |
| Device Description: | iBond Self Etch(new formulation is anacetone/water-based formulation of lightactivated methylacrylate resins. |
| Intended use of the device: | See indications for use below. |
| Indications for use: | iBond Self Etch (new formulation) it intendedfor use by dental professionals, for thebonding of direct light-cured compositerestorations (including Polyglas® andcopomers), bonding of indirect restorations incombination with a light curing luting cement;porcelain, polyglas®, and compositerestorations (inlays, onlays, veneers crowns)and sealing hypersensitive areas of teeth. |
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image shows the word "Heraeus" in a stylized font. The letters are outlined with a double border, giving them a hollow appearance. The text is presented in a horizontal arrangement, with each letter clearly distinguishable despite the decorative outline.
Summary of the Technological Characteristics of the New Device Compared to the predicate Device HK Bond K063062:
The formula of the proven all-in-one adhesive has been refined. The modifications include the addition of a stabilizer the exchange of a rheological additive. The enhanced iBOND Self Etch new formulation is now conveniently useable and storable at room temperature (up to 25°C). The adhesive no longer requires shaking. The product fulfills the internal specification. The basic fundamental scientific technology remains the same as well as the indications for use.
| CLEARED iBOND Self Etch | NEW iBOND Self Etch | |
|---|---|---|
| (BHT)- K063062 | (ISEA-EC) | |
| Content of BHT | 750 ppm | Same |
| Indications for Use | iBOND Self Etch is used forbonding of direct light-curedcomposite restorations(including Polyglas® andcopomers), bonding ofindirect restorations incombination with a light-curing luting cement;porcelain, Polyglas®, andcomposite restorations(inlays, onlays, veneers,crowns) and sealinghypersensitive areas ofteeth. | Same |
| Visual Appearance | Yellowish liquid,homogeneous, withoutsediment | Same |
| pH | <2,00 | Same |
| Refractive index | 1,421-1,426 | Same |
| Application | Application in 1 layer | Same |
| Dwell time | 20s | Same |
| Curing time | 20s | Same |
| Compatibility | Compatible with direct lightcured composite, light curedluting cement, porcelain | Same |
Similarities as Compared to Predicate:
{2}------------------------------------------------
|--|--|--|
| CHARLERS CREEN LE LE LE SE MERICLE CARRIES CLAND SERVICE | A S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S SPolvelas®and composite | COLLECTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTIO |
|---|---|---|
| restorations------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
Note: For formulation similarities as compared to predicate, please see section 11 of this submission.
Differences as Compared to Predicate:
| CLEARED iBOND Self Etch | NEW iBOND Self Etch | |
|---|---|---|
| (BHT)-K063062 | (ISEA-EC) | |
| Shear Bond Strength | >15 MPa | ≥20 MPa |
| Storage condition | Refrigeration required | No refrigeration required |
| Handling | Shaking necessary | No shaking necessary |
Note: For formulation differences as compared to predicate, please see section 11 of this submission.
Results Summary:
The biological compatibility of iBOND Self Etch was verified in accordance with the international standard EN ISO 10993.
The medical devices iBOND Self Etch and new formulation were extracted with hydrophilic and lipophilic extraction medium according to EN ISO 10993-12. Leachable compounds detected in n-hexane, isopropanole and saline extracts are considered covered by the toxicological tests performed with iBOND Self Etch.
Considering the low exposure of the patient and animal welfare requirements, no in vivo toxicity studies were performed with the uncured or cured material.
The biocompatibility of iBOND Self Etch _new formulation in the aforementioned indication is documented and the benefit/risk-relation has to be judged as positive.
An allergenic potential in predisposed persons cannot be excluded completely due to the presence of monomers such as acrylates and methacrylates.
Conclusions Drawn From Non-Clinical and Clinical Data:
The refined formula of the proven all-in-one adhesive is substantially equivalent to cleared iBOND Self Etch.
A biocompatibility evaluation has been performed by a toxicologist for iBOND Self Etch _ new formulation. It was confirmed that the product meets the requirements of ISO 10993 and it is concluded that the safety of iBOND Self Etch __new formulation is equivalent to that of the predicate device.
The risk analysis acc. ISO 14791 was carried out for iBOND Self Etch _new formulation. It is concluded that safety of iBOND Self Etch _new formulation for the intended use is substantially equivalent to the predicate device. iBOND Self Etch_new formulation and the predicate
Page 3 of 4
{3}------------------------------------------------
HERAEUS
formula have the same indication for use, warnings and contraindications. When used in accordance with the instruction for use, by qualified personnel, iBOND Self Etch _new formulation is safe and effective, as indicated for the intended use.
. . . .
{4}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized emblem with three curved lines, resembling a person with outstretched arms, positioned to the right. Encircling the emblem is the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
December 7, 2012
Ms. Jamie Mearna Associate Quality Assurance & Regulatory Manager Heraeus Kulzer, Limited Liability Company 300 Heraeus Way SOUTH BEND IN 46614
Re: K123278
Trade/Device Name: iBond Self Etch Regulation Number: 21 CFR 872.3200 Regulation Name: Resin Tooth Bonding Agent Regulatory Class: II Product Code: KLE Dated: September 25, 2012 Received: November 19, 2012
Dear Ms. Mearna:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{5}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must or any I vature the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical Or ice-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please n you desire specific advisiboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Kwame O. Ulmer
Anthony D. Watson, B.S., M.S., M.B.A. Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{6}------------------------------------------------
Indications for Use
510(k) Number (if known): _ K (23279
Device Name: iBond Self Etch
Indications for Use:
iBond Self Etch is an acetone/water-based formulation of light-activated methylacrylate resins.
iBond Self Etch is used for bonding of direct light-cured composite restorations (including Polyglas and copomers), bonding of indirect restorations in combination with a light-curing luting cement; porcelain, Polyglas®, and composite restorations (inlays, onlays, veneers, crowns) and sealing hypersensitive areas of teeth.
Over-The-Counter Use Prescription Use AND/OR (21 CFR 807 Subpart C) (Part 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
i 2012.12.07
Susan Runner DDS, MA 15:06:19
-05'00'
(Division Sign-Off) (UNIsion Sign-On)
Division of Anesthesiology, General Hospital Infection Control, Dental Devices
Page 1 of .
510(k) Number:
§ 872.3200 Resin tooth bonding agent.
(a)
Identification. A resin tooth bonding agent is a device material, such as methylmethacrylate, intended to be painted on the interior of a prepared cavity of a tooth to improve retention of a restoration, such as a filling.(b)
Classification. Class II.